Perrigo Company (PRGO) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Perrigo Company

NYSE•Healthcare•Drug Manufacturers - Specialty & Generic

$13.66+0.07(0.01%)After hours

Market Cap

$1.89B

P/S

0.5x

P/B

0.8x

Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

How this company scores

WeakMetricSide Score: 26/100

Strongest: Balance Sheet & Red Flags (9/25); weakest: Profitability (3/25).

Profitability3/25

Growth6/25

Balance Sheet & Red Flags9/25

Cash & Earnings Quality8/25

Strengths

Improving margins

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 666.6x5y range 666.6x – 1006.8x

P/S · 0.5x5y range 0.3x – 2.6x

Currently below its 20-quarter median.

P/B · 0.8x5y range 0.5x – 1.3x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 653.7% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Red Flag

FCF consistently trails net income (avg 0.7x) — earnings may be inflated by non-cash items or aggressive accounting.

Price & Volume

Market Cap $1.89B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $4.14B
Q. Revenue: $1.02B
TTM EBITDA: $-1.27B
TTM Op. Income: $-1.56B
Q. Op. Income: $23.50M
TTM Net Income: $-1.73B
Q. Net Income: $74.50M
EPS: $0.54
Shares Out.: $139.10M

$4.14B in TTM revenue declined 4.2% YoY, reaching $1.02B last quarter. TTM EBITDA of $-1.27B and TTM operating income of $-1.56B show growth is flowing through to the bottom line. However, net income is negative at $1.73B — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 7 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 30.7%
EBITDA Margin: 6.3%
Op. Margin: 2.3%
Net Margin: 7.3%

Op. margin of 2.3% is down 2.0% YoY — costs are rising relative to revenue. Net margin at 7.3% and gross margin of 30.7% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 0.5x
P/B Ratio: 0.8x

P/S of 0.5x and P/B of 0.8x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $7.61B
Cash: $399.70M
Long-Term Debt: $3.28B
Book Value: $2.52B
D/E Ratio: 1.3
Debt/EBITDA: 50.6

With $7.61B in assets and $3.28B in long-term debt, D/E is 1.3and book value is $2.52B — moderate leverage. Over the past year, debt/equity is up 61% — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $82.60M
TTM Free Cash Flow: $119.30M
FCF Margin: 2.9%
FCF / Net Income: -0.1

TTM FCF of $119.30M on $82.60M in operating cash flow. The FCF / Net Income ratio of -0.1x means the business consumes cash — it is not yet self-funding. Over the past year, free cash flow is down 54% — an improving trend.